Medication Adherence and Discontinuation of Aripiprazole Once-Monthly 400 mg (AOM 400) Versus Oral Antipsychotics in Patients with Schizophrenia or Bipolar I Disorder: A Real-World Study Using US Claims Data
Sign Up to like & getrecommendations! Published in 2018 at "Advances in Therapy"
DOI: 10.1007/s12325-018-0785-y
Abstract: IntroductionFew studies have compared adherence between long-acting injectable antipsychotics, especially for newer agents like aripiprazole once-monthly 400 mg (AOM 400; aripiprazole monohydrate) and oral antipsychotics, in patients with schizophrenia or bipolar I disorder (BD-I) in a… read more here.
Keywords: aom 400; patients schizophrenia; cohort; discontinuation ... See more keywords
Assessment of adherence to oral antipsychotic medications: What has changed over the past decade?
Sign Up to like & getrecommendations! Published in 2020 at "Schizophrenia Research"
DOI: 10.1016/j.schres.2019.11.022
Abstract: INTRODUCTION In a previous review, spanning 3 decades, we found that self-report and other non-objective measures were the primary means of assessing adherence to oral antipsychotic medications for individuals with schizophrenia. Moreover, consensus regarding the… read more here.
Keywords: decade; medication; oral antipsychotic; adherence ... See more keywords
Switching stable patients with schizophrenia from their oral antipsychotics to aripiprazole lauroxil: a post hoc safety analysis of the initial 12-week crossover period
Sign Up to like & getrecommendations! Published in 2018 at "CNS Spectrums"
DOI: 10.1017/s1092852918000986
Abstract: Objective Switching antipsychotic medications is common in patients with schizophrenia who are experiencing persistent symptoms or tolerability issues associated with their current drug regimen. This analysis assessed the safety of switching from an oral antipsychotic… read more here.
Keywords: week; patients schizophrenia; analysis; safety ... See more keywords